托法替布在中重度慢性斑块状银屑病患者中的获益-风险特征:六项临床试验的汇总分析
汇总一项II期、四项III期和一项长期延伸研究共5204患者年的托法替布治疗数据,评估中重度斑块状银屑病的获益与风险。托法替布5 mg和10 mg每日两次在第16周所有疗效终点均优于安慰剂,疗效维持至52周,生活质量改善且耐受良好。10 mg每日两次疗效优于5 mg每日两次,获益-风险特征与其他系统性治疗一致。
要点
- 托法替布5 mg和10 mg每日两次在第16周所有疗效终点均优于安慰剂,疗效维持52周。
- 托法替布10 mg每日两次疗效优于5 mg每日两次。
- 关注的安全性事件(除带状疱疹外)发生率与其他系统性银屑病治疗的已发表文献和医疗数据库相似。
核心结论
- 托法替布在中重度银屑病中的获益-风险特征与其他系统性治疗一致。
研究设计与样本
- 汇总一项II期、四项III期和一项长期延伸研究,共5204患者年的托法替布治疗数据。
主要发现
- 托法替布5 mg和10 mg每日两次在第16周所有疗效终点均优于安慰剂,持续治疗52周应答维持。
- 托法替布改善患者生活质量且耐受良好。
- 关注的安全性事件(除带状疱疹外)发生率与已发表文献和医疗数据库中其他系统性银屑病治疗相似。
- 托法替布10 mg每日两次疗效优于5 mg每日两次。
关键数值与推荐
- 疗效终点包括医师整体评估为「清除」或「几乎清除」、银屑病面积和严重度指数较基线改善≥75%和≥90%(共同主要终点),以及第16周和52周皮肤病生活质量指数评分、医院焦虑抑郁量表抑郁评分和瘙痒严重度条目评分的改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate-to-severe chronic plaque psoriasis. OBJECTIVES: To consider the benefits and risks of tofacitinib in patients with moderate-to-severe psoriasis. METHODS: Data were pooled from one phase II, four phase III and one long-term extension study comprising 5204 patient-years of tofacitinib treatment. Efficacy end points included patients achieving Physician's Global Assessments of 'clear' or 'almost clear', ≥ 75% and ≥ 90% reduction in Psoriasis Area and Severity Index (coprimary end points) and improvements in Dermatology Life Quality Index score, Hospital Anxiety and Depression Scale depression score and Itch Severity Item score, at weeks 16 and 52. Safety data were summarized for 3 years of tofacitinib exposure. RESULTS: Tofacitinib 5 and 10 mg twice daily (BID) showed superiority over placebo for all efficacy end points at week 16, with response maintained for 52 weeks of continued treatment. Tofacitinib improved patients' quality of life and was well tolerated. Rates of safety events of interest (except herpes zoster) were similar to those in the published literature and healthcare databases for other systemic psoriasis therapies. Tofacitinib 10 mg BID demonstrated greater efficacy than 5 mg BID. CONCLUSIONS: Tofacitinib has a benefit-risk profile in moderate-to-severe psoriasis consistent with that of other systemic treatments.
引用
- Strober BE, Gottlieb AB, van de Kerkhof PCM, et al. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. Br J Dermatol. 2018. PMID: 30188571. doi:10.1111/bjd.17149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。